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1. Introduction 
A protein activator specific for bovine brain cyclic 
3’,5’-nucleotide phosphodiesterase was discovered 
several years ago during the course of enzyme purification 
[ 1 ] . The existence of this activator raises the question 
of its physiological role in modulating phosphodiesterase 
activity. To answer this question, we undertook two 
lines of approach. One was to correlate the tissue or 
cellular distribution as well as tissue developmental 
changes of phosphodiesterase and its activator. We 
found that although the activities of the enzyme and 
the activator paralleled one another on a subcellular 
basis, they varied from tissue to tissue and during 
ontogenetic development of the tissues [2]. The 
variability may be a result of cellular heterogeneity or 
multiple forms of phosphodiesterase (for example, 
activator-dependent and activator-independent 
enzyme) [2-51. Although parallel distribution of the 
two activities on a subcellular basis suggests possible 
physiological relevance, it does not reveal the mode 
of activation of phosphodiesterase by the activator. 
Another approach was to characterize the’activator 
and to elucidate its mode of action. We found that the 
activator increases the V,, of the enzyme and 
decreases its K, for cyclic AMP and that stimulation 
of phosphodiesterase is a stoichiometric process [6,7]. 
We further found that the activator binds Ca++ and 
that chelation of Ca++ by EGTA renders the activator 
inactive. It was suggested that the Ca++-activator 
complex is the active form of phosphodiesterase [8]. 
Recently, Teo and Wang, working with bovine heart, 
[9] and Kakiuchi et al., working with rat brain [lo] 
reached a similar conclusion. 
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Experiments described here show that Ca” causes 
the formation of the enzyme-activator complex, and 
that the rate of formation of the active complex is 
rapid enough to account for the fast catabolism of 
cyclic AMP in vivo. 
2. Materials and methods 
2.1. Preparation of phosphodiesterase and its activator 
from bovine brain 
Phosphodiesterase was purified through DEAE- 
cellulose chromatography [ 1 I] ; the enzyme at this 
stage is activator-deficient and dependent on an 
exogenous activator for maximum activity. The 
activator was purified through a DEAlScellulose 
column [8,12]. 
2.2. Assay of phosphodiesterase and its activator 
Phosphodiesterase was assayed with S’nucleotidase 
of snake venom as an auxillary enzyme using a two- 
stage procedure as described previously [7]. The 
activator was determined by its ability to stimulate an 
activator-deficient phosphodiesterase [7]. 
2.3. Measurement of protein 
Protein was estimated by the spectrophotometric 
technique of Warburg and Christian [ 131. 
3. Results and discussion 
The protein activator of bovine brain phospho- 
diesterase is dissociable from the enzyme by a salt 
North-Holland Publishing Company - Amsterdam 
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Fig. 1. Ca*-dependent association of phosphodiesterase and its activator as shown by filtration in a Sephadex G-200 column 
(95 X 2.5 cm). Panel A.: The column was equilibrated with a buffer containing 20 mM Tris-Cl (pH 8.0), 100 mM NaCl, 0.1 mM 
dithiothreitol, and 0.1 mM EGTA (Buffer A) at 4°C. Thirteen milligrams of an activator-deficient phosphodiesterase and 8 wg of a 
highly purified activator in 2.5 ml of a buffer containing 40 mM Tris-Cl (pH 8.0), 0.1 mM dithiothreitol and 0.1 mM EGTA was 
incubated for 15 min at 30°C and then applied to the column. The column was eluted with Buffer A; fractions of 3.5 ml were 
collected at a flow rate of 24 ml/hr. Aliquots were assayed separately for the activator and for phosphodiesterase in the presence 
or absence of an exogenous activator by a two-stage procedure as described previously [ 71. The reaction mixture contained 40 mM 
Tris-Cl (pH 8.0), 3 mM MgSO,, 0.05 mM CaCl, , 2 mM cyclic AMP and an appropriate amount of phosphodiesterase and/or 
activator. The trace of EGTA carried over from the elution buffer into the assay mixture did not affect either the activity of 
phosphodiesterase or its activator. Panel B.: The column was equilibrated with a buffer containing 20 mM Tri-Cl (pH 8.0), 
100 mM NaCl, 0.1 mM dithiothreitol and 0.1 mM C&l, (Buffer B). Thirteen milligrams of an activator-deficient phosphodiesterase 
and 8 pg of a highly purified activator in 2.5 ml of a buffer containing 40 mM Tris-Cl (pH 8.0), 0.1 mM dithiothreitol and 0.1 mM 
CaCl 2 was incubated for 15 min at 30°C and then loaded on the column. The column was eluted with Buffer B. Fractions were 
collected and assayed as in Panel A. Panel C.: Conditions were the same as those in Panel B except phosphodiesterase and the 
activator were applied to the column separately. The column was calibrated with apoferritin (mol. wt 460 000) pyruvate kinase 
(mol. wt 238 000), bovine serum albumin (mol. wt 68 000), ovalbumin (mol. wt 45 000) and soybean trypsin inhibitor (mol. wt 
21 600) according to Andrews [14]. 
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gradient on a DEAE-cellulose column [ 111. Dissocia- 
tion of the two proteins reduces the activity of 
phosphodiesterase to its basal level. Chelation of Ca++ 
in the activator by EGTA also reduces phospho- 
diesterase to its basal activity [8]. The possibility that 
chelation of Ca” by EGTA may cause dissociation of 
the two proteins and hence the reduction of enzymic 
activity was examined. A mixture of phosphodiesterase 
and its activator was passed through a Sephadex G-200 
column that had been equilibrated with EGTA. Fig. IA 
shows that phosphodiesterase was resolved into two 
active fractions: the first peak coincided with the 
exclusion volume whereas the second peak correspond- 
ed to a mol. wt of 170 000. Phosphodiesterase activity 
was considerably higher when assayed in the presence 
of an exogenous activator than in its absence. This was 
due to the fact that the activator, originally mixed with 
the enzyme, was eluted after both peaks of enzyme 
activity and none was detected with the enzyme. This 
experiment shows that chelation of Ca” by EGTA 
dissociates the activator from the enzyme, making it 
less active. In this experiment, the activator was eluted 
at a position corresponding to a mol. wt of 33 000. It 
has been shown elsewhere that the molecular weight 
of the activator obtained by gel filtration under this 
condition is approximately twice that obtained with 
other methods [8]. 
In a separate experiment (fig. 1 B), the enzyme- 
activator mixture was passed through the same column 
that had been equilibrated with Ca++ instead of EGTA. 
In contrast to the result shown in fig. 1 A, the activator 
was eluted with the enzyme and phosphodiesterase 
activity was virtually the same whether assayed in the 
presence or absence of an exogenous activator. 
Further, the second activity peak was shifted to a 
position corresponding to a higher mol. wt of 230 000, 
suggesting that this form of the enzyme retained 
approximately two moles of the activator [IS] . In 
addition, the activator which was not associated with 
the enzyme was eluted ahead of its usual position as 
a broad peak. This presumably resulted from associa- 
tion-dissociation of the enzyme and the activator 
during the course of filtration through the column. 
Fig. 1 C illustrates a control experiment in which 
the enzyme and the activator were passed separately 
through the column previously equilibrated with Ca*. 
Both the enzyme and the activator were eluted at 
positions identical to those in Fig. 1 A, demonstrating 
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that Ca” did not affect the behavior of these proteins 
on gel filtration. 
It may be concluded from these experiments that 
in the presence of Ca++ the enzyme and the activator 
form a complex, whereas in its absence the two 
proteins remain dissociated. Since the activator binds 
Ca++ [8,16] , the cation may function as follows: 
Ca++  Activator * Ca” -Activator 
[Enzyme] + Ca” -Activator * [Enzyme-Ca”-Activator] 
inactive active 
Although the experiments depicted in fig. 1 clearly 
show the Ca”-dependent formation of the enzyme- 
activator complex, they do not indicate the time for 
this process to take place. The rate of formation or 
dissociation of the enzyme-activator complex was 
next examined. Since the enzyme-activator complex 
is the active species, the rate of increase of 
phosphodiesterase activity by Ca* would be a measure 
of the rate of complex formation. Similarly, the rate 
of decrease of enzymic activity by EGTA would be a 
measure of the rate of complex dissociation. Fig. 2 
shows the change of phosphodiesterase activity upon 
the addition or the chelation of Ca”. The initial portion 
of the curve depicts the basal rate of cyclic AMP hydro- 
lysis in the absence of Ca”. As soon as Ca*was added 
to the reaction mixture, the rate of hydrolysis was in- 
creased immediately. The enhanced rate was maintained 
until excess EGTA was added, thereby reducing the rate 
of hydrolysis to its prestimulated level. This experiment 
demonstrates that both the formation and the dissocia- 
tion of the enzyme-activator complex are rapid. 
Kakiuchi and his coworkers described a Ca”+- and 
Mg”-dependent phosphodiesterase from rat brain and 
found that a micromolar Ca++ enhanced the stimulation 
of phosphodiesterase by the activator [ 17,181. 
Recently, they reported that the association of the 
enzyme with the activator was dependent on Ca” [ISI . 
Phosphodiesterase in the brain is localized in the 
nerve endings [ 19,201. Increasing evidence indicates 
that cyclic AMP is closely involved with nervous 
activity [21] . Addition of a depolarizing agent such 
as K’ to brain slices resulted in a marked elevation of 
tissue level of cyclic AMP [22] . Depolarizing squid 
axons by increasing the external K’ concentration 
caused a pronounced increase of Ca” influx [23]. The 
increase of cyclic AMP may be temporally related to 
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Fig. 2. Effect of Ca* or EGTA on the rate of cyclic AMP hydrolysis catalyzed by bovine brain phosphodiesterase. A reaction 
mixture of 25 ml contained 40 mM Tris-Cl (pH 8.0), 3 mM MgSO,, 0.02 mM EGTA, 2.6 mg of an activator-deficient 
phosphodiesterase and 0.05 mg of a highly purified activator. The reaction at 30°C was initiated by 2 mM cyclic AMP; at 10 and 
20 min, Ca# (40 PM) and EGTA (60 PM) were added to the reaction mixture, respectively. At times indicated, 0.5 ml of the 
reaction mixture was transferred to a tube kept at 100°C to terminate the enzyme activity. Phosphodiesterase was assayed by a 
two-stage procedure [7]. 
the enhanced Ca” influx when the nervous tissue is 
stimulated. The increase of intracellular Ca” may 
activate phosphodiesterase, which then restores the 
concentration of cyclic AMP to its prestimulated 
level. 
A protein activator specific for phosphodiesterase 
has-now been described by several other groups of 
workers [9,17,24]. The work presented here as well 
as that from other laboratories suggests that the in 
vivo regulation of phosphodiesterase by the activator 
may be related to the Ca” flux, as first suggested by 
Kakiuchi et al. [ 181. This notion appears credible 
from the following considerations: first, stimulation 
of phosphodiesterase requires micromolar Ca” which 
is within the physiological range of this cation [23] ; 
second, the activator is generally in excess of 
phosphodiesterase [7] so that the Ca* flux could be 
rate-determining; and third, the response of the 
enzyme-activator system to Ca” is rapid (fig. 2) and 
therefore is compatible with the fast catabolism of 
cyclic AMP [25,26] . Although direct in vivo 
experimental data in support of this notion is still 
lacking, the observation of Namm et al. [27] that 
cyclic AMP level in rat heart was increased or decreas- 
ed by perfusion of the heart with a Cafe-free or a 
Cat-rich medium, respectively, is in accord with this 
view. 
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